Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.

摘要: Abstract Objective There have been only few studies investigating the role of PSMA ligands in therapy response assessment metastasized castration resistant prostate cancer (mCRPC) cases. In this study we aimed at evaluating capability 68Ga- prostate-specific membrane antigen (PSMA) -I&T positron emission tomography/computerized tomography (PET/CT) therapeutic patients under docetaxel for (PCa). Material and methods The clinical records all mCRPC treated with referred to our department 68Ga-PSMA I&T PET/CT imaging were retrospectively analysed. Sixteen (mean age 69 years, range 52–82 years) castration-resistant receiving palliative had undergone scan included study. was done specific (PSA) levels measured baseline before administration (PET1) after least 3 cycles (range 4–12) chemotherapy (PET2). Patient-based as well lesion-based comparison PET2 findings PET1 done. Results change (decrease) observed lymph node gland/prostatic bed SUVmax values treatment compared pretreatment found be statistically significant (p = 0.033). 3/16 (19%) classified progressive disease (PD), 4/16 (25%) stable (SD), 9/16 (56%) partial remission (PR) radiologically. An increasing PSA trend (IT) 4 a decreasing (DT) (18%). Nine showed ≥50% (56%). Of showing SD, IT, BR. 9 who PR on PET studies, 8 BR 1 patient DT. Conclusion Imaging great concordance biochemical evaluation terms levels, especially good therapy. also successful identifying paradoxical decline levels.